Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
- Sponsored Content
- Gene Therapies
Addressing Critical Issues in Cell and Gene Therapy ManufacturingAddressing Critical Issues in Cell and Gene Therapy Manufacturing
Josh Snow
December 10, 2021
1 Min Read
Sponsored by Mirus Bio
Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show great promise for treatment of diseases from genetic disorders to cancer. Accordingly, there is an unprecedented need for high titer and large-scale viral vector manufacturing processes to support the growing number of researchers developing biotherapeutics for immunotherapy.
Download this Special Report, highlighting:
Evolutions of gene therapy manufacturing
Improvements to GMP raw-material sourcing.
Role of transfection reagents like VirusGEN® GMP as a turnkey element to optimize virus production.
Transfection reagent quality and regulatory considerations.
Fill out the form below to read the complete report now.
You May Also Like
Webinars
Mar 18 - Mar 21, 2025
Mar 18 - Mar 21, 2025
SLASH TIME FROM BENCH TO BEDSIDE: Cutting-edge biomanufacturing for mAbs, vaccines, and advanced therapies. Bright ideas, bold science, and big innovations—delivering efficiency, precision, and quality through every phase of bioprocessing.
Learn MoreInnovative Technology
Sponsored Content
